恒瑞医药：HRS-5635注射液纳入拟突破性治疗品种公示名单

Core Viewpoint - Heng Rui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has had its HRS-5635 injection included in the list of proposed breakthrough therapies by the National Medical Products Administration's Drug Review Center, with a public announcement period of 7 days [1] Group 1 - HRS-5635 injection is a new generation liver-targeted siRNA drug developed by the company for the treatment of chronic hepatitis B [1] - Phase II clinical trial results indicate that HRS-5635 has the potential to improve functional cure rates for chronic hepatitis B while demonstrating good safety characteristics [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2 - The cumulative research and development investment for the HRS-5635 injection project has reached approximately 151.68 million yuan [1]